COVID-19 vaccination in adults with inflammatory bowel disease
Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now availabl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-05-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848231173130 |
| _version_ | 1797822249081765888 |
|---|---|
| author | Megan Lutz Sarah Lazarus Freddy Caldera |
| author_facet | Megan Lutz Sarah Lazarus Freddy Caldera |
| author_sort | Megan Lutz |
| collection | DOAJ |
| description | Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now available for the prevention of COVID-19, with most data available for mRNA vaccines. Patients with IBD have a robust humoral response to vaccination with rates of seroconversion exceeding 95% following a two-dose mRNA vaccine series and 99% following a three-dose mRNA series, although those on certain therapies including anti-tumor necrosis factor α agents may have lower antibody concentrations and waning of antibodies over time. Additionally, rates of cell-mediated immune response, even in those patients with IBD who did not have evidence of humoral immunity, are high. Vaccines are safe and have not been associated with flares in disease activity. Gastroenterology providers should take an active role in ensuring patients with IBD are appropriately vaccinated against COVID-19. |
| first_indexed | 2024-03-13T10:05:14Z |
| format | Article |
| id | doaj.art-412bc560cd034bfc9cbd9187014deae9 |
| institution | Directory Open Access Journal |
| issn | 1756-2848 |
| language | English |
| last_indexed | 2024-03-13T10:05:14Z |
| publishDate | 2023-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-412bc560cd034bfc9cbd9187014deae92023-05-22T13:03:34ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482023-05-011610.1177/17562848231173130COVID-19 vaccination in adults with inflammatory bowel diseaseMegan LutzSarah LazarusFreddy CalderaPatients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now available for the prevention of COVID-19, with most data available for mRNA vaccines. Patients with IBD have a robust humoral response to vaccination with rates of seroconversion exceeding 95% following a two-dose mRNA vaccine series and 99% following a three-dose mRNA series, although those on certain therapies including anti-tumor necrosis factor α agents may have lower antibody concentrations and waning of antibodies over time. Additionally, rates of cell-mediated immune response, even in those patients with IBD who did not have evidence of humoral immunity, are high. Vaccines are safe and have not been associated with flares in disease activity. Gastroenterology providers should take an active role in ensuring patients with IBD are appropriately vaccinated against COVID-19.https://doi.org/10.1177/17562848231173130 |
| spellingShingle | Megan Lutz Sarah Lazarus Freddy Caldera COVID-19 vaccination in adults with inflammatory bowel disease Therapeutic Advances in Gastroenterology |
| title | COVID-19 vaccination in adults with inflammatory bowel disease |
| title_full | COVID-19 vaccination in adults with inflammatory bowel disease |
| title_fullStr | COVID-19 vaccination in adults with inflammatory bowel disease |
| title_full_unstemmed | COVID-19 vaccination in adults with inflammatory bowel disease |
| title_short | COVID-19 vaccination in adults with inflammatory bowel disease |
| title_sort | covid 19 vaccination in adults with inflammatory bowel disease |
| url | https://doi.org/10.1177/17562848231173130 |
| work_keys_str_mv | AT meganlutz covid19vaccinationinadultswithinflammatoryboweldisease AT sarahlazarus covid19vaccinationinadultswithinflammatoryboweldisease AT freddycaldera covid19vaccinationinadultswithinflammatoryboweldisease |